抗血管内皮生长因子药物治疗早产儿视网膜病变的复发研究现状及进展

Current status and progress of recurrence of retinopathy in prematurity after intravitreal injection with anti-vascular endothelial growth factor drugs

玻璃体腔注射抗VEGF药物治疗早产儿视网膜病变(ROP)是目前研究热点,其用于治疗Ⅰ区ROP可取得明确疗效。目前应用于临床的抗VEGF药物包括贝伐单抗、雷珠单抗、阿柏西普、康柏西普等。但近年多项研究证实相较于传统激光光凝治疗,抗VEGF药物治疗ROP复发率升高,复发时间更迟,应延长随访期及可能需要重复注射药物。目前由于缺乏大规模前瞻性临床研究,多种抗VEGF药物治疗ROP的复发率、复发时间窗、危险因素和治疗方法等尚无明确定论。抗VEGF药物治疗ROP还需积累更多循证医学证据。

Intravitreal injection of anti-VEGF drugs for the treatment of retinopathy of prematurity(ROP)is a hot topic of research,and it can be used to treat the ROP(Ⅰzone).The current anti-VEGF drugs include bevacizumab,ranibizumab,aflibercept and conbercept,etc.However,in recent years,several studies have confirmed that anti-VEGF drugs have an increased recurrence rate and a longer recurrence time than conventional laser photocoagulation therapy.The follow-up period should be extended and repeated injections may be required.Due to the lack of large-scale prospective clinical studies,the recurrence rate,time window of recurrence,risk factors and treatment methods of various anti-VEGF drugs for ROP are still unclear.Anti-VEGF drugs in the treatment of ROP needs to accumulate more evidence-based medical evidence.